TACE/ADAM-17: A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer

Nipun Merchant, Igor Voskresensky, Christopher M. Rogers, Bonnie LaFleur, Peter J. Dempsey, Ramona Graves-Deal, Frank Revetta, A. Coe Foutch, Mace L. Rothenberg, Mary K. Washington, Robert J. Coffey

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Purpose: Activation of the epidermal growth factor receptor (EGFR) requires cell surface cleavage of EGFR ligands, uptake of soluble ligand by the receptor, and initiation of EGFR tyrosine kinase activity. We define these collective events as the EGFR axis. Transforming growth factor-α (TGF-α) and amphiregulin are two EGFR ligands that are delivered preferentially to the basolateral surface of polarized epithelial cells where the EGFR resides. TACE/ADAM-17 (tumor necrosis factor-α converting enzyme/a disintegrin and metalloprotease) has been implicated in ectodomain cleavage of TGF-α and amphiregulin. Experimental Design: Using a human polarizing colorectal cancer (CRC) cell line, HCA-7, and a tissue array of normal colonic mucosa and primary and metastatic CRC, we determined the intracellular localization of TACE and the effects of EGFR axis inhibition in CRC. Results: Herein, we show that TACE is localized to the basolateral plasma membrane of polarized HCA-7 cells. TACE is overexpressed in primary and metastatic CRC tumors compared with normal colonic mucosa; the intensity of its immunoreactivity is inversely correlated with that of TGF-α and amphiregulin. Pharmacologic blockade of HCA-7 cells with an EGFR monoclonal antibody, a selective EGFR tyrosine kinase inhibitor, and a selective TACE inhibitor results in concentration-dependent decreases in cell proliferation and active, phosphorylated mitogen-activated protein kinase. Combining suboptimal concentrations of these agents results in cooperative growth inhibition, increased apoptosis, and reduced mitogen-activated protein kinase pathway activation. Furthermore, an EGFR tyrosine kinase - resistant clone of HCA-7 cells is growth-inhibited by combined monoclonal antibody and TACE inhibition. Conclusion: These results implicate TACE as a promising target of EGFR axis inhibition in CRC.

Original languageEnglish (US)
Pages (from-to)1182-1191
Number of pages10
JournalClinical Cancer Research
Volume14
Issue number4
DOIs
StatePublished - Feb 15 2008
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Transforming Growth Factors
Therapeutics
Protein-Tyrosine Kinases
Ligands
Mitogen-Activated Protein Kinases
Mucous Membrane
ADAM17 Protein
Monoclonal Antibodies
Disintegrins
Metalloproteases
Growth
Research Design
Clone Cells
Tumor Necrosis Factor-alpha
Epithelial Cells
Cell Proliferation
Cell Membrane
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

TACE/ADAM-17 : A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. / Merchant, Nipun; Voskresensky, Igor; Rogers, Christopher M.; LaFleur, Bonnie; Dempsey, Peter J.; Graves-Deal, Ramona; Revetta, Frank; Foutch, A. Coe; Rothenberg, Mace L.; Washington, Mary K.; Coffey, Robert J.

In: Clinical Cancer Research, Vol. 14, No. 4, 15.02.2008, p. 1182-1191.

Research output: Contribution to journalArticle

Merchant, N, Voskresensky, I, Rogers, CM, LaFleur, B, Dempsey, PJ, Graves-Deal, R, Revetta, F, Foutch, AC, Rothenberg, ML, Washington, MK & Coffey, RJ 2008, 'TACE/ADAM-17: A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer', Clinical Cancer Research, vol. 14, no. 4, pp. 1182-1191. https://doi.org/10.1158/1078-0432.CCR-07-1216
Merchant, Nipun ; Voskresensky, Igor ; Rogers, Christopher M. ; LaFleur, Bonnie ; Dempsey, Peter J. ; Graves-Deal, Ramona ; Revetta, Frank ; Foutch, A. Coe ; Rothenberg, Mace L. ; Washington, Mary K. ; Coffey, Robert J. / TACE/ADAM-17 : A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 4. pp. 1182-1191.
@article{a4e29335acf6401886c9092db3fc5525,
title = "TACE/ADAM-17: A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer",
abstract = "Purpose: Activation of the epidermal growth factor receptor (EGFR) requires cell surface cleavage of EGFR ligands, uptake of soluble ligand by the receptor, and initiation of EGFR tyrosine kinase activity. We define these collective events as the EGFR axis. Transforming growth factor-α (TGF-α) and amphiregulin are two EGFR ligands that are delivered preferentially to the basolateral surface of polarized epithelial cells where the EGFR resides. TACE/ADAM-17 (tumor necrosis factor-α converting enzyme/a disintegrin and metalloprotease) has been implicated in ectodomain cleavage of TGF-α and amphiregulin. Experimental Design: Using a human polarizing colorectal cancer (CRC) cell line, HCA-7, and a tissue array of normal colonic mucosa and primary and metastatic CRC, we determined the intracellular localization of TACE and the effects of EGFR axis inhibition in CRC. Results: Herein, we show that TACE is localized to the basolateral plasma membrane of polarized HCA-7 cells. TACE is overexpressed in primary and metastatic CRC tumors compared with normal colonic mucosa; the intensity of its immunoreactivity is inversely correlated with that of TGF-α and amphiregulin. Pharmacologic blockade of HCA-7 cells with an EGFR monoclonal antibody, a selective EGFR tyrosine kinase inhibitor, and a selective TACE inhibitor results in concentration-dependent decreases in cell proliferation and active, phosphorylated mitogen-activated protein kinase. Combining suboptimal concentrations of these agents results in cooperative growth inhibition, increased apoptosis, and reduced mitogen-activated protein kinase pathway activation. Furthermore, an EGFR tyrosine kinase - resistant clone of HCA-7 cells is growth-inhibited by combined monoclonal antibody and TACE inhibition. Conclusion: These results implicate TACE as a promising target of EGFR axis inhibition in CRC.",
author = "Nipun Merchant and Igor Voskresensky and Rogers, {Christopher M.} and Bonnie LaFleur and Dempsey, {Peter J.} and Ramona Graves-Deal and Frank Revetta and Foutch, {A. Coe} and Rothenberg, {Mace L.} and Washington, {Mary K.} and Coffey, {Robert J.}",
year = "2008",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-07-1216",
language = "English (US)",
volume = "14",
pages = "1182--1191",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - TACE/ADAM-17

T2 - A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer

AU - Merchant, Nipun

AU - Voskresensky, Igor

AU - Rogers, Christopher M.

AU - LaFleur, Bonnie

AU - Dempsey, Peter J.

AU - Graves-Deal, Ramona

AU - Revetta, Frank

AU - Foutch, A. Coe

AU - Rothenberg, Mace L.

AU - Washington, Mary K.

AU - Coffey, Robert J.

PY - 2008/2/15

Y1 - 2008/2/15

N2 - Purpose: Activation of the epidermal growth factor receptor (EGFR) requires cell surface cleavage of EGFR ligands, uptake of soluble ligand by the receptor, and initiation of EGFR tyrosine kinase activity. We define these collective events as the EGFR axis. Transforming growth factor-α (TGF-α) and amphiregulin are two EGFR ligands that are delivered preferentially to the basolateral surface of polarized epithelial cells where the EGFR resides. TACE/ADAM-17 (tumor necrosis factor-α converting enzyme/a disintegrin and metalloprotease) has been implicated in ectodomain cleavage of TGF-α and amphiregulin. Experimental Design: Using a human polarizing colorectal cancer (CRC) cell line, HCA-7, and a tissue array of normal colonic mucosa and primary and metastatic CRC, we determined the intracellular localization of TACE and the effects of EGFR axis inhibition in CRC. Results: Herein, we show that TACE is localized to the basolateral plasma membrane of polarized HCA-7 cells. TACE is overexpressed in primary and metastatic CRC tumors compared with normal colonic mucosa; the intensity of its immunoreactivity is inversely correlated with that of TGF-α and amphiregulin. Pharmacologic blockade of HCA-7 cells with an EGFR monoclonal antibody, a selective EGFR tyrosine kinase inhibitor, and a selective TACE inhibitor results in concentration-dependent decreases in cell proliferation and active, phosphorylated mitogen-activated protein kinase. Combining suboptimal concentrations of these agents results in cooperative growth inhibition, increased apoptosis, and reduced mitogen-activated protein kinase pathway activation. Furthermore, an EGFR tyrosine kinase - resistant clone of HCA-7 cells is growth-inhibited by combined monoclonal antibody and TACE inhibition. Conclusion: These results implicate TACE as a promising target of EGFR axis inhibition in CRC.

AB - Purpose: Activation of the epidermal growth factor receptor (EGFR) requires cell surface cleavage of EGFR ligands, uptake of soluble ligand by the receptor, and initiation of EGFR tyrosine kinase activity. We define these collective events as the EGFR axis. Transforming growth factor-α (TGF-α) and amphiregulin are two EGFR ligands that are delivered preferentially to the basolateral surface of polarized epithelial cells where the EGFR resides. TACE/ADAM-17 (tumor necrosis factor-α converting enzyme/a disintegrin and metalloprotease) has been implicated in ectodomain cleavage of TGF-α and amphiregulin. Experimental Design: Using a human polarizing colorectal cancer (CRC) cell line, HCA-7, and a tissue array of normal colonic mucosa and primary and metastatic CRC, we determined the intracellular localization of TACE and the effects of EGFR axis inhibition in CRC. Results: Herein, we show that TACE is localized to the basolateral plasma membrane of polarized HCA-7 cells. TACE is overexpressed in primary and metastatic CRC tumors compared with normal colonic mucosa; the intensity of its immunoreactivity is inversely correlated with that of TGF-α and amphiregulin. Pharmacologic blockade of HCA-7 cells with an EGFR monoclonal antibody, a selective EGFR tyrosine kinase inhibitor, and a selective TACE inhibitor results in concentration-dependent decreases in cell proliferation and active, phosphorylated mitogen-activated protein kinase. Combining suboptimal concentrations of these agents results in cooperative growth inhibition, increased apoptosis, and reduced mitogen-activated protein kinase pathway activation. Furthermore, an EGFR tyrosine kinase - resistant clone of HCA-7 cells is growth-inhibited by combined monoclonal antibody and TACE inhibition. Conclusion: These results implicate TACE as a promising target of EGFR axis inhibition in CRC.

UR - http://www.scopus.com/inward/record.url?scp=39749085844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749085844&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1216

DO - 10.1158/1078-0432.CCR-07-1216

M3 - Article

C2 - 18281553

AN - SCOPUS:39749085844

VL - 14

SP - 1182

EP - 1191

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -